ITRMF (Iterum Therapeutics) Other Current Receivables: $0.10 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Iterum Therapeutics Other Current Receivables?

Iterum Therapeutics ITRMF Other Current Receivables is $0.10 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

Iterum Therapeutics's Other Current Receivables for the quarter that ended in Sep. 2025 was $0.10 Mil.

Iterum Therapeutics's quarterly Other Current Receivables increased from Mar. 2025 ($0.02 Mil) to Jun. 2025 ($0.08 Mil) and increased from Jun. 2025 ($0.08 Mil) to Sep. 2025 ($0.10 Mil).

Iterum Therapeutics's annual Other Current Receivables declined from Dec. 2022 ($0.42 Mil) to Dec. 2023 ($0.23 Mil) and declined from Dec. 2023 ($0.23 Mil) to Dec. 2024 ($0.07 Mil).

Iterum Therapeutics Other Current Receivables Related Terms

Iterum Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics Other Current Receivables Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only 0.87 1.21 0.42 0.23 0.07

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.07 0.02 0.08 0.10

Iterum Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.10 Mil mean?
Iterum Therapeutics (ITRMF) has a Other Current Receivables of $0.10 Mil as of Sep. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Iterum Therapeutics and its competitors.
Is Iterum Therapeutics' Other Current Receivables too high?
Iterum Therapeutics' current Other Current Receivables is $0.10 Mil.
How does Iterum Therapeutics' Other Current Receivables compare to HEPA and MTNB?
Iterum Therapeutics' Other Current Receivables of $0.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current Other Current Receivables is $0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Other Current Receivables of $0.10 Mil. The current Other Current Receivables is $0.10 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Other Current Receivables is $0.10 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.